What is the optimal treatment for bone lesions, including patients with renal insufficiency?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massachusetts General Hospital, Boston, US. We asked: what is the optimal treatment for bone lesions, including patients with renal insufficiency?

In this podcast, Elizabeth O'Donnell discusses how bone-directed therapy is an important component of multiple myeloma (MM) therapy. She describes the study which led to the FDA approval of denosumab, before describing results from the ongoing phase II, single-arm study of denosumab in patients with MM with real insufficiency (creatinine clearance < 30). She focuses on the safety profile and adverse events including neurotoxicities and hypocalcemia.

See acast.com/privacy for privacy and opt-out information.